Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LSS | P48449 | 4/20 | 0.55 |
| ▸ | DRD2 | P14416 | 2/20 | 0.48 |
| ▸ | HTR1A | P08908 | 1/20 | 0.48 |
| ▸ | HTR2A | P28223 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 10/20 | 0.46 |
| ▸ | HRH1 | P35367 | 2/20 | 0.45 |
| ▸ | HRH2 | P25021 | 1/20 | 0.45 |
| ▸ | MAOB | P27338 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4746202 | 0.90 | MAOB (0.54) | MAOB | |
| SCHEMBL4747494 | 0.90 | HRH3 (0.46) | DRD2MEN1KMT2AHRH3HRH1 | |
| SCHEMBL4746681 | 0.89 | HRH3 (0.46) | DRD2MEN1KMT2AHRH3HRH1 | |
| SCHEMBL4743286 | 0.88 | DRD2 (0.48) | LSSDRD2MEN1KMT2AHRH3 | |
| SCHEMBL4743300 | 0.88 | HRH3 (0.57) | DRD2MEN1KMT2AHRH3HRH1 | |
| SCHEMBL4745400 | 0.85 | HTR1A (0.50) | LSSDRD2HTR1AHTR2AMEN1 | |
| SCHEMBL4746760 | 0.83 | HRH3 (0.51) | DRD2MEN1KMT2AHRH3HRH1 | |
| SCHEMBL4745404 | 0.81 | F10 (0.49) | DRD2MEN1KMT2AHRH3HRH1 | |
| SCHEMBL4746206 | 0.80 | HRH3 (0.57) | MEN1KMT2AHRH3 | |
| SCHEMBL4745363 | 0.79 | HRH3 (0.56) | MEN1KMT2AHRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008107320-A1 | PIPERIDINE AND PIPERAZINE DERIVATIVES USED AS ANTI-NEOPLASIC AGENTS OR CELL PROLIFERATION INHIBITORS | CEREP (FR) | 2008-09-12 | — | — | WO | disclosed |